JAC Advance Access originally published online on November 13, 2007
Journal of Antimicrobial Chemotherapy 2008 61(1):206-209; doi:10.1093/jac/dkm438
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Original research |
Long-distance interactive expert advice in highly treatment-experienced HIV-infected patients
1 Lluita contra la SIDA Foundation, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain 2 Hospital Sant Pau, Barcelona, Spain 3 Hospital General, Valladolid, Spain 4 Hospital Xeral, Vigo, Spain 5 Hospital Clínico, Valencia, Spain 6 Hospital Virgen de la Victoria, Málaga, Spain 7 Hospital Ramón y Cajal, Madrid, Spain 8 National Hemophilia Center, Sheba Medical Center, Tel Aviv, Israel
* Corresponding author. Tel: +34-93-4657897; Fax: +34-93-4657602; E-mail: jmllibre{at}flsida.org
Received 12 September 2007; returned 3 October 2007; revised 9 October 2007; accepted 12 October 2007
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionFundingTransparency declarationsReferences |
|---|
Objectives: To determine the feasibility and outcomes of long-distance interactive expert advice for treatment-experienced patients.
Methods: HIV-1-infected patients on failing highly active antiretroviral therapy (HAART) were prospectively submitted for consultation by treating physicians to an expert panel using a standard e-mail form including: resistance tests, antiretroviral history, adherence, CD4 counts, HIV-1-RNA levels and HCV/HBV co-infection. Conference calls (CCs) were scheduled monthly to discuss 10 new patients.
Results: One hundred and fifteen patients were discussed (86% male; 45% intravenous drug users). The median length of HIV infection was 10 years and subjects were treated for a median of 8 years with a median of 5.25 previous HAART regimens. Ninety per cent were triple-class experienced [nucleoside reverse transcriptase inhibitors (NRTIs)/non-NRTIs (NNRTIs)/protease inhibitors (PIs)]. Median CD4 cell count was 298 cells/mm3 and median viral load was 19 700 copies/mL. Overall, 60% had 
5 reverse transcriptase mutations and 67% had 5 protease mutations, and most patients were NNRTI-resistant. Drugs more frequently recommended by experts were: lamivudine/emtricitabine > tenofovir > abacavir > zidovudine > didanosine > stavudine (NRTIs) and tipranavir > lopinavir > atazanavir > saquinavir (PIs). Enfuvirtide was recommended in 65% of cases. Concordance between recommended and prescribed regimens was 74.7%. Virtually all discordances were due to patient refusal of complex regimens. Outcomes at 24 weeks: HIV-1-RNA <50 copies/mL in 42% of patients, HIV-1-RNA <400 copies/mL in 59.4% of patients and median CD4 increase was 77 (14–140) cells/mm3.
Conclusions: Long-distance interactive expert advice is feasible for complex treatment-experienced HIV patients using e-mail and CCs. Adherence to treatment recommendations is high, with encouraging viro-immunological outcomes at 24 weeks. This strategy merits further investigation, especially in clinical settings where availability of local experts is limited.
Keywords: teleconference , genotypic resistance testing , expert opinion , antiretroviral treatment , salvage therapy
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionFundingTransparency declarationsReferences |
|---|
Implementing updated science into routine practice is a daily challenge for clinicians caring for HIV-1-infected patients failing antiretroviral therapy (ART). Genotypic resistance testing is strongly recommended in all guidelines, extensively used and recently linked to enhanced survival.1–3
However, genotypic resistance testing is complex, reported in a straightforward three-level output (susceptible, intermediate and resistant) and does not include recommendations on any specific first choice ART drug or combination. In addition, previous drug history and genotypic resistance testing are not considered.4
We and others have outlined the importance of expert advice in treatment decisions.5–8 Patients receiving highly active antiretroviral therapy (HAART) regimens based on expert advice have significantly better virological outcomes. All current guidelines recommend to seek expert advice whenever possible to help in the interpretation of genotypic resistance testing.1,2,9 However, the availability of HIV resistance experts is limited and moreover clinician adherence to recommendations is usually low,10 the main reason being patient's concern about toxicity or compliance and clinician's disagreement. The absence of live discussion and direct contact between experts and clinicians might play a key role.
Conference calls (CCs) are an affordable option that allows a real-time open discussion regardless of distances.11
We hypothesized that a scheduled CC programme could narrow the gap between HIV experts and clinical providers and improve the accuracy of salvage therapy.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionFundingTransparency declarationsReferences |
|---|
Unselected HIV specialists working in 10 public hospitals in Spain, university tertiary hospitals and small community hospitals, participated in the programme voluntarily. This allowed a broad nationwide representation of patients (age > 18 years) with genotypic resistance testing recently performed while on stable therapy (
12 weeks) if their clinician asked for advice. In most patients, a virtual phenotype (VP) was also available (VircoType HIV-1, Belgium). Current CD4 cell count and biochemistry were collected, with sex, age, risk behaviour, length of HIV-1 infection, body weight, presence of lipodystrophy, chronic B/C hepatitis, concomitant disorders and therapies, previous adverse events and hypersensitivity, ART switch reasons and previous genotypic resistance testing.
CCs were scheduled monthly. Cases were prospectively reviewed by a panel of three experts, active in resistance research for 10 years, and involved in guidelines and resistance education.12
A report itemizing resistance profiles and ART recommendations was returned, stating whether it was based on reported medical evidence or only on expert opinion, with warnings against the initiation of specific agents, when necessary.
A power point slide presentation including key information of all cases was sent to be displayed in everyone's own computer. All participants and two experts joined in every CC (90 min). One expert reviewed the recommendation on a case-by-case basis. There was an open dialogue where treating physicians could ask further explanations about the number or type of drugs selected.
The 24 week viro-immunological success and the rate of implementation of the advice were evaluated. When complete viral suppression was considered unachievable, a complete or partial treatment interruption was advised.13 These patients were excluded only from the analysis of virological success.
Statistical analysis used SPSS Version 12.0. Variables were described as mean (SD) or median [interquartile range (IQR)]. Student's t-test or Mann–Whitney rank sum and 
2 tests were used as appropriate.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionFundingTransparency declarationsReferences |
|---|
Characteristics of discussed patients (n = 115) are shown in Table 1.
|
Reduced nucleoside reverse transcriptase inhibitor (NRTI) susceptibility was common, with marginal or virtually no NRTI activity in >60%. Nearly all patients received recycled NRTIs. Non-NRTI (NNRTI) resistance was present in 74% of patients, although the estimated rate was actually higher considering treatment history. Similarly, lamivudine resistance was also underestimated due to loss of M184V mutation.
The most frequently encountered mutations are shown in Table 2. There were no restrictions on discussed patients; therefore, they probably reflect the landscape of treatment failure in advanced patients in Europe.
|
A complete salvage therapy was advised in 86/115 (75%) patients. In the remainder, two different approaches were advised depending on current/nadir CD4, clinical status, previous toxicities and the expected availability of investigational drugs: a bridging NRTI-only regimen (mainly co-formulated zidovudine/lamivudine/abacavir and tenofovir, 16/115, 14% of patients) or a complete structured CD4-guided treatment interruption (13/115, 11.3% of patients) in selected patients with widespread resistance, CD4 >500 cells/mm3, and adherence or toxicity as their major problem (HAART reinitiation when CD4 <350 cells/mm3, viral load >100 000 copies/mL or in the unlikely event of clinical progression).14 Special emphasis was made on avoiding NNRTIs or protease inhibitors (PIs). The CD4 count decline at 24 weeks in these patients was 28 cells/mm3.
Lamivudine/emtricitabine were included in 88.2% of recommendations, and in decreasing order: tenofovir (77.4%), abacavir (67.8%), zidovudine (47%), didanosine (42%) and stavudine (32%). NNRTIs (efavirenz or nevirapine, 3:1 ratio) were included in only 22.5% (26/115) of patients, 30% naive to NNRTIs and the remaining due to NNRTI hypersusceptibility pattern or resistance not being documented. Boosted PIs were always included in regimens: tipranavir (67.8%), lopinavir (46.1%), atazanavir (45.1%), fosamprenavir (37.4%) or saquinavir (34.8%). Enfuvirtide was included in 65%. Darunavir and etravirine were not yet routinely available.
There was a complete agreement between recommendations and clinician's implementation in 86/115 (74.7%) patients. Causes for discordance were: treatment withdrawal (13.2%), patient refusal of enfuvirtide, abacavir or lopinavir (4.3%) and treatment intolerance (enfuvirtide, 1.8%). Only one case (0.9%) of discordance was due to clinician's disagreement. Seven patients were lost to follow-up.
Treatment response at 24 weeks: viral suppression <50 copies/mL in 42% of patients and <400 copies/mL in 59.4%. A drop of 1 log10 HIV-1-RNA copies/mL was seen in 80%, and the median CD4 cell count increase was 77 (14–140) cells/mm3.
All clinicians rated the CC experience as very useful and relevant to their practice and remained involved in the extended follow-up.
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionFundingTransparency declarationsReferences |
|---|
HIV-1-infected individuals harbouring resistance, despite the challenges of interpreting complex resistance data, require accurately designed salvage regimens to control their HIV replication.
Because our understanding of how best to interpret genotypic resistance testing continues to evolve and due to the complex patterns of mutations with synergistic or antagonistic interactions, patients are best managed with expert guidance.1,2
This is the first study to prospectively evaluate the feasibility of live long-distance interactive expert advice in HIV infection using CCs. It demonstrates that this strategy is feasible in a nationwide setting, with quick, efficient and inexpensive data exchange between clinicians and an expert panel. This intervention achieved an encouraging rate of viro-immunological success. The mutational patterns seen are close to those observed in pivotal studies of treatment-experienced patients but rates of success have been higher despite using the same drugs.15,16 Our study, however, lacked a control group, so the efficacy data should be interpreted with caution. Indeed, the concordance of recommended with prescribed treatments (74.7%) was very high, outperforming the concordance seen in other expert advice studies in the HIV field without live CCs.5,6,10 In fact, discordances were due to patient refusal of complex regimens. The direct contact between treating clinicians and HIV experts may have played an important role in this concordance success. This allowed bi-directional flow of data, and the proper interpretation of genotypic resistance testing, the patient's clinical status, treatment history and CD4 counts.
Fourteen per cent of our patients harboured widespread resistance without a potentially successful salvage regimen. The optimal management in this setting has not yet been defined. Temporizing with a maintenance NRTI-only regimen, waiting for two new active agents, prevents further accumulation of mutations to PIs/NNRTIs and exerts partial antiviral pressure, reducing drug exposure.13,17 Short-term mortality, clinical progression and CD4 decay were not seen in our study. These patients were among the most worrisome for their treating physicians.
The most prevalent reverse transcriptase mutation patterns found reflect the long exposure to NRTIs. Unfortunately, key mutations conferring higher resistance to zidovudine or stavudine and the wider degree of cross-resistance have been frequently encountered (41L, 210W and 215Y/F). Although extensive PI mutations were also seen, newer agents (tipranavir) retained complete or partial activity. Not surprisingly, tipranavir was the most frequently recommended PI (darunavir was not available at that time). Enfuvirtide was advised in two out of every three patients, with efforts made by experts to provide adequate ‘protection’ due to its low genetic barrier and rapid development of resistance, a fact not always considered in routine clinical practice by treating physicians.
A somewhat surprising finding was the presence of advanced triple-class resistance in asymptomatic patients with high CD4 counts (>500 cells) and low viral loads (<20 000 copies/mL) who were otherwise doing well. Prior exposure to mono/dual NRTI, initial HAART with unboosted PI, poor adherence and extensive prior therapy have been identified as risk factors.18
The overall CC efficacy might be even greater with patients being discussed at earlier stages before widespread resistance has evolved. Other additional potential benefits of CCs were not evaluated. A pharmacoeconomic study evaluating cost savings due to reduction of useless expensive treatments, drug toxicity and avoiding further accumulation of resistance mutations should also be explored. A physician's education and its impact on future patient care merit consideration. Indeed, there was a considerable educational benefit to everyone joining the discussion, providing all participants with valuable training and updating.
CCs might not only be useful to small centres with limited knowledge of HIV-1 resistance, but also to higher units whose physicians are mainly devoted to other areas of HIV knowledge.
Feasible cost-effective strategies are urgently needed as HAART evolves. Availability of local resistance experts may be limited, despite availability of genotypic resistance testing. CCs might be a suitable solution, providing expert advice along with continued education. This CC straightforward strategy is a realistic possibility in a nationwide setting, achieves a very high concordance between advised and eventually prescribed regimens and can improve the complex management of treatment-experienced patients, especially for clinicians with limited knowledge of HIV-1 resistance. Its value could further improve if patients were discussed at earlier stages.
|
Funding |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionFundingTransparency declarationsReferences |
|---|
The present study received unrestricted funding from Bayer HealthCare, Spain, and GlaxoSmithKline, Spain, to support the expenses of the conference call programme. The funders played no role in the design and conduct of the study, analysis, interpretation of the data, preparation, review or approval of the manuscript. All the authors participated as part of their routine work.
|
Transparency declarations |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionFundingTransparency declarationsReferences |
|---|
None to declare.
|
Acknowledgements |
|---|
This work was presented in part at the Fourth European HIV Drug Resistance Workshop, Monte Carlo, Monaco, 2006 (abstract 65). We gratefully acknowledge Cecilia Alcaraz for coordinating the study, collecting the information, translating data into Powerpoint presentations and requesting the follow-up data, as well as Raquel López-Blázquez for statistical analysis, Aurora Berra and Paula Palma for their support in the dynamics of the conferences and Roger Paredes for reviewing the manuscript prior to submission.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionFundingTransparency declarationsReferences |
|---|
1 Hammer SM, Saag MS, Schechter M, et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA (2006) 296:827–43.
2 Panel on Clinical Practices for Treatment in HIV Infection convened by Department of Health and Human Services (DHHS). Guidelines For The Use Of Antiretroviral Agents in HIV-Infected Adults and Adolescents, 10 October 2006. http://aidsinfo.nih.gov (31 August 2007, date last accessed).
3 Palella FJ, Armon C, Chmiel JS, et al. Enhanced survival associated with use of HIV susceptibility testing among HAART-experienced patients in the HIV Outpatient Study (HOPS). In: Abstracts of the Thirteenth Conference on Retroviruses and Opportunistic Infections, Denver, CO, 2006. VA, USA: Foundation for Retrovirology and Human Health. Abstract 654.
4 Zolopa AR, Lazzeroni LC, Rinehart A, et al. Accuracy, precision, and consistency of expert HIV type 1 genotype interpretation: an international comparison (The Guess Study). Clin Infect Dis (2005) 41:92–9.[CrossRef][Web of Science][Medline]
5 Tural C, Ruiz L, Holtzer C, et al. Clinical utility of HIV-1 genotyping and expert advice: the Havana trial. AIDS (2002) 16:209–18.[CrossRef][Web of Science][Medline]
6 Baxter JD, Mayers DL, Wentworth DN, et al. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. AIDS (2000) 14:F83–93.[CrossRef][Web of Science][Medline]
7 Bossi P, Peytavin G, Ait-Mohand H, et al. GENOPHAR: a randomized study of plasma drug measurements in association with genotypic resistance testing and expert advice to optimize therapy in patients failing antiretroviral therapy. HIV Med (2004) 5:352–9.[CrossRef][Web of Science][Medline]
8 Badri SM, Adeyemi OM, Max BE, et al. How does expert advice impact genotypic resistance testing in clinical practice? Clin Infect Dis (2003) 37:708–13.[CrossRef][Web of Science][Medline]
9 Expert Panel of GESIDA and the Spanish AIDS Plan. Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infections (Update January 2007). Enferm Infecc Microbiol Clin (2007) 25:32–53.[CrossRef][Web of Science][Medline]
10 Torti C, Quiros-Roldan E, Regazzi M, et al. A randomized controlled trial to evaluate antiretroviral therapy guided by rules-based or phenotype-driven HIV-1 genotypic drug-resistance interpretation with or without concentration-controlled intervention: the resistance and dosage adapted regimens (RADAR) study. Clin Infect Dis (2005) 40:1828–36.[CrossRef][Web of Science][Medline]
11
DeAngelis CD, Berwick DM. Author in the room: a teleconference series to accelerate health care improvement. JAMA (2005) 293:1004.
12 Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: Fall 2006. Top HIV Med (2006) 14:125–30.[Medline]
13 Deeks SG, Hoh R, Neilands TB, et al. Interruption of treatment with individual therapeutic drug classes in adults with multidrug-resistant HIV-1 infection. Clin Infect Dis (2005) 192:1537–44.
14 Ruiz L, Paredes R, Gomez G, et al. Antiretroviral therapy interruption guided by CD4 cell counts and plasma HIV-1 RNA levels in chronically HIV-1-infected patients. AIDS (2007) 21:169–78.[Web of Science][Medline]
15 Hicks CB, Cahn P, Cooper DA, et al. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials. Lancet (2006) 368:466–75.[CrossRef][Web of Science][Medline]
16
Lazzarin A, Clotet B, Cooper D, et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med (2003) 348:2186–95.
17 Castagna A, Danise A, Menzo S, et al. Lamivudine monotherapy in HIV-1-infected patients harbouring a lamivudine-resistant virus: a randomized pilot study (E-184V study). AIDS (2006) 20:795–803.[Web of Science][Medline]
18 Napravnik S, Keys JR, Quinlivan EB, et al. Triple-class antiretroviral drug resistance: risk and predictors among HIV-1-infected patients. AIDS (2007) 21:825–34.[Web of Science][Medline]
CiteULike 
Connotea 
Del.icio.us What's this?
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||